



## Model List of Essential Medicines



### **Atezolizumab** [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#) Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#) Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach Hepatocellular carcinoma of liver](#)



### **Bevacizumab** [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

[Hepatocellular carcinoma of liver](#)



### **Blinatumomab** [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial

Indications

[B lymphoblastic leukaemia or lymphoma, not elsewhere classified](#)



### **Cemiplimab** [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)  
Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung](#)



### **Daratumumab** [General information](#)

Section

## Immunomodulators

- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

### Indications

[Plasma cell myeloma](#)



## **Dostarlimab** [General information](#)

### Section

#### Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

### Indications

[Other specified malignant neoplasms of corpus uteri](#)



## **Durvalumab** [General information](#)

### Section

#### Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

### Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Hepatocellular carcinoma of liver](#) [Malignant neoplasms of biliary tract, distal bile duct](#) [Malignant neoplasm of intrahepatic bile ducts](#) [Malignant neoplasms of gallbladder](#) [Malignant neoplasms of proximal biliary tract, cystic duct](#)



## **Filgrastim** [General information](#)

### Section

#### Immunomodulators

- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

### Indications

[Acquired neutropaenia](#)



## **Ipilimumab** [General information](#)

### Section

#### Immunomodulators

- Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

### Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Squamous cell carcinoma of oesophagus](#) [Melanoma of skin](#)



## **Lenalidomide** [General information](#)

### Section

#### Immunomodulators

- Oral > Solid: 25 mg

### Indications

[Plasma cell myeloma](#)



## **Nivolumab** [General information](#)

### Section

#### Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

### Indications

Therapeutic equivalent to [pembrolizumab](#) for [Melanoma of skin](#) [Other specified malignant neoplasms of bronchus or lung](#) [Melanoma of skin](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Squamous cell carcinoma of oesophagus](#) [Adenocarcinoma of oesophagogastric junction](#) [Adenocarcinoma of stomach](#)



### **Pegfilgrastim [General information](#)**

Section

Immunomodulators

- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

[Acquired neutropaenia](#)



### **Pembrolizumab [General information](#)**

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

Indications

[Melanoma of skin](#) [Malignant neoplasms of cervix uteri](#) [Other specified malignant neoplasms of large intestine](#) [Other specified malignant neoplasms of bronchus or lung](#) [Adenocarcinoma of stomach](#) [Squamous cell carcinoma of hypopharynx and variants](#) [Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Squamous cell carcinoma of oropharynx](#) [Squamous cell carcinoma of nasopharynx](#) [Malignant neoplasms of oesophagogastric junction](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Carcinoma of breast, specialised type](#) [Squamous cell carcinoma of oesophagus](#) Therapeutic equivalent to [nivolumab](#) for [Melanoma of skin](#)



### **Thalidomide [General information](#)**

Section

Immunomodulators

- Oral > Solid: 50 mg

Indications

[Plasma cell myeloma](#)



### **Tislelizumab [General information](#)**

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

[Malignant neoplasms of urinary tract](#) [Hodgkin lymphoma](#) [Other specified malignant neoplasms of bronchus or lung](#) [Squamous cell carcinoma of oesophagus](#)



### **Toripalimab [General information](#)**

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

[Malignant neoplasms of nasopharynx](#) [Squamous cell carcinoma of oesophagus](#)



### **Tremelimumab [General information](#)**

Section

Immunomodulators

- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#) [Other specified malignant neoplasms of bronchus or lung](#)